Alcohol and cancer risk

Alcohol consumption is causally linked to at least seven cancer types: cancers of the mouth, pharynx, larynx, esophagus, colorectum, liver, and breast. Risk increases with the amount consumed, and available evidence does not establish a clearly safe level of intake with respect to cancer. Globally, alcohol is estimated to account for approximately 4 to 6% of all cancer cases, making it one of the most important modifiable contributors to cancer burden worldwide.

Ethanol is metabolized primarily to acetaldehyde, a highly reactive compound that forms DNA adducts and impairs nucleotide excision repair, allowing mutations to accumulate in proliferating cells. Acetaldehyde is classified by the International Agency for Research on Cancer (IARC) as a Group 1 carcinogen. Beyond direct DNA damage, alcohol metabolism generates reactive oxygen species (ROS) through cytochrome P450 2E1 (CYP2E1) activity, promoting oxidative stress and lipid peroxidation that further damages DNA and cellular membranes. For breast cancer specifically, alcohol impairs hepatic estrogen clearance and may stimulate estrogen receptor activity, elevating circulating estrogen levels through a hormonal mechanism independent of acetaldehyde. Alcohol also disrupts folate metabolism by competing with folate absorption and increasing urinary folate excretion, reducing the availability of methyl groups essential for proper DNA synthesis and methylation. For liver cancer, chronic alcohol exposure drives inflammation, fibrosis, and eventually cirrhosis, creating a pro-carcinogenic hepatic microenvironment in which cell proliferation is accelerated. Alcohol may also act as a solvent that enhances mucosal penetration of other carcinogens such as those in tobacco smoke, which partly explains the multiplicatively elevated cancer risk in people who both drink and smoke.

An umbrella systematic review synthesizing evidence across clinical interventions, policies, and dose-response health risks confirmed that alcohol is a major modifiable cause of cancer morbidity and premature mortality, with dose-response relationships across consumption levels indicating that less alcohol is associated with lower risk and no safe cancer-free threshold has been established. A genetic association study found that interactions between polymorphisms in the human 8-oxoguanine DNA glycosylase 1 (hOGG1) gene, a key base excision repair enzyme, and alcohol drinking influenced nasopharyngeal carcinoma (NPC) risk, illustrating that DNA repair capacity modifies the carcinogenic impact of alcohol at the individual level. A review of non-traditional risk factors for esophageal cancer noted that while tobacco and alcohol together account for a large proportion of esophageal squamous cell carcinoma (ESCC), they do not fully explain regional heterogeneity in incidence, suggesting that additional lifestyle and environmental factors contribute. A systematic review and meta-analysis of genetic susceptibility in oral squamous cell carcinoma (OSCC) confirmed that alcohol, alongside tobacco use, is among the most consistently implicated risk factors in studies examining genetic-environmental interactions.

Smokers who also drink face multiplicatively elevated risk for cancers of the upper aerodigestive tract, including the mouth, pharynx, larynx, and esophagus, because the two exposures interact synergistically. Individuals with variants in the aldehyde dehydrogenase 2 (ALDH2) gene, common in East Asian populations, accumulate acetaldehyde more rapidly after drinking and face markedly elevated esophageal cancer risk even at relatively modest alcohol consumption levels. Women may be more susceptible than men to alcohol-related breast cancer, as estrogen metabolism is affected even at low intake levels. For colorectal cancer, risk increases approximately linearly with alcohol intake across population studies. People who begin drinking heavily in early adulthood and sustain that pattern over decades accumulate the greatest lifetime exposure and associated risk.

The evidence linking alcohol to cancer risk is strong and consistent, supported by large prospective cohort studies, systematic reviews, mechanistic research, and the IARC's Group 1 carcinogen classification for alcohol in relation to multiple cancer sites. Dose-response relationships are well characterized for most alcohol-related cancers, particularly esophageal, oral, and colorectal cancers. For breast cancer, evidence that even light to moderate drinking increases risk has become more consistent in recent large studies and meta-analyses. Most evidence is observational, as randomized controlled trials assigning people to alcohol consumption levels are not ethically feasible. Active areas of debate include whether drinking pattern and beverage type influence cancer risk beyond total ethanol content, and how residual confounding by other lifestyle factors affects study results.

Evidence consistently shows that alcohol increases cancer risk, with no established safe threshold for several cancer types. The relationship is dose-dependent, meaning lower consumption is associated with lower risk, but research has not identified a level that carries no risk at all. This finding has led several national health agencies to revise guidance toward recommending minimal or no alcohol for cancer prevention, though the individual absolute risk from light drinking remains small for most cancer types.